https://www.selleckchem.com/pr....oducts/Semagacestat(
No patients developed acute liver insufficiency, were admitted to the ICU, or had to undergo transplantation. Follow-up data (median of 1.3 years) were available for 30 patients. LTLI was observed in only one patient, who had previously received treatment with azoles. CONCLUSIONS Our study suggests that the administration of micafungin to patients with end-stage liver disease does not imply a higher risk of developing STLI or LTLI.Mast cells (MCs) are granular cells of the innate immune system which develop from CD34+/CD1
Like
Comment
Share
